Use of mTOR inhibitors for treatment of familial adenomatous polyposis
US11191750B2 · kind B2 · utility
2Cited by
169References
20Claims
0Family size
Assignee
Inventors
Key dates
| Filing date | Jun 29, 2020 |
| Grant date | Dec 7, 2021 |
| Priority date | — |
| Expiry date | Jun 29, 2040 |
Classification
- Technology area (CPC A)Human Necessities
- CPC primaryA61P35/04
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
Disclosed are methods and compositions for the treatment or prevention of intestinal polyps or prevention of cancer in a patient who has been identified as being at risk for developing intestinal polyps or intestinal cancer. The disclosed methods and compositions include rapamycin, a rapamycin analog, or another such inhibitor of the target of rapamycin (TOR).
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.